RHHBY and CHGCY Related Headlines
Go Back- FDA approves Genentech's Enspryng for thyroid eye disease
- FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
- FDA grants priority review to Genentech's Enspryng for rare disease MOGAD
- U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
- Roche gets FDA clearance for two new laboratory analytical units
- Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories
- Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets
- /C O R R E C T I O N -- Roche/
- Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation
- Roche gets CE mark for blood test detecting Alzheimer's gene variant
- Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease
- New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools
- Roche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities
- Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche
- Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025
RHHBY and CHGCY Related Press Releases
Go Back- FDA Approves Genentech’s Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
- U.S. FDA Grants Priority Review for Genentech’s Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments
- Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories
- Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets
- /C O R R E C T I O N -- Roche/
- Roche expands mass spectrometry menu to include steroid assays receiving CLIA 'moderate complexity' designation
- Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease
- New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools
- Roche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities
- Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche
- Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025
